roxadustat + darbepoetin alfa

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Renal Anemia Associated With Chronic Renal Failure (CRF)

Conditions

Renal Anemia Associated With Chronic Renal Failure (CRF)

Trial Timeline

Mar 28, 2013 → Sep 15, 2014

NCT ID

NCT01888445

About roxadustat + darbepoetin alfa

roxadustat + darbepoetin alfa is a phase 2 stage product being developed by Astellas Pharma for Renal Anemia Associated With Chronic Renal Failure (CRF). The current trial status is completed. This product is registered under clinical trial identifier NCT01888445. Target conditions include Renal Anemia Associated With Chronic Renal Failure (CRF).

What happened to similar drugs?

20 of 20 similar drugs in Renal Anemia Associated With Chronic Renal Failure (CRF) were approved

Approved (20) Terminated (0) Active (0)

✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved

✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved

✅Tacrolimus, Prograf®Astellas PharmaApproved

✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved

✅Tacrolimus + CyclosporineAstellas PharmaApproved

✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02952092	Phase 3	Completed	Nov 30, 2016	Mar 15, 2018	Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02021318	Phase 3	Completed	Mar 12, 2014	Nov 6, 2019	Anemia in Chronic Kidney Disease in Non-dialysis Patients
NCT01888445	Phase 2	Completed	Mar 28, 2013	Sep 15, 2014	Renal Anemia Associated With Chronic Renal Failure (CRF)

Competing Products

20 competing products in Renal Anemia Associated With Chronic Renal Failure (CRF)

See all competitors

Product	Company	Stage	Hype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109	MBX Biosciences	Phase 1	23
LY3473329	Eli Lilly	Phase 1	29
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
SPR001	Spruce Biosciences	Phase 2	25
SPR001	Spruce Biosciences	Phase 2	25
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
Tildacerfont	Spruce Biosciences	Phase 2	17
Drotrecogin alfa activated (Xigris)	Eli Lilly	Phase 2	35
LY3819469	Eli Lilly	Phase 1	29
Atezolizumab + Cabozantinib	Chugai Pharmaceutical	Phase 3	32
DS-6000a + DS-6000a	Daiichi Sankyo	Phase 1	33
DS-1093a	Daiichi Sankyo	Phase 1	29
CS-3150	Daiichi Sankyo	Phase 3	40
AGS-16C3F	Astellas Pharma	Phase 1	29
AGS-16M8F	Astellas Pharma	Phase 1	29
CP-461	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
YM178	Astellas Pharma	Phase 1	29
intravenous immunoglobulins (IVIG)	Astellas Pharma	Phase 1	29
bixalomer	Astellas Pharma	Pre-clinical	26